$9.00 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter

Brokerages forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will report sales of $9.00 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Heron Therapeutics’ earnings. The lowest sales estimate is $7.00 million and the highest is $10.00 million. Heron Therapeutics posted sales of $1.28 million in the same quarter last year, which suggests a positive year over year growth rate of 603.1%. The firm is expected to report its next quarterly earnings results on Thursday, February 22nd.

On average, analysts expect that Heron Therapeutics will report full year sales of $9.00 million for the current year, with estimates ranging from $27.71 million to $31.00 million. For the next fiscal year, analysts forecast that the business will report sales of $67.03 million per share, with estimates ranging from $65.00 million to $68.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%.

Several equities analysts recently weighed in on HRTX shares. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Mizuho restated a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a report on Tuesday, January 16th. Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the company a “buy” rating in a report on Monday, January 15th. Finally, Zacks Investment Research cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $28.82.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 19.93% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of HRTX. Legal & General Group Plc lifted its position in Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 2,383 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the third quarter valued at about $206,000. Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the third quarter valued at about $223,000. HighTower Advisors LLC raised its position in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its position in Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,724 shares in the last quarter. Hedge funds and other institutional investors own 98.37% of the company’s stock.

Heron Therapeutics (NASDAQ:HRTX) opened at $20.70 on Tuesday. The stock has a market capitalization of $1,130.00, a P/E ratio of -5.46 and a beta of 1.87. Heron Therapeutics has a one year low of $12.70 and a one year high of $24.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/06/9-00-million-in-sales-expected-for-heron-therapeutics-inc-hrtx-this-quarter.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply